

Bibliography

Peer reviewed articles

1. W Wynendaele, AT van Oosterom, A Pawinski, EA de Bruijn, RA Maes. Angiogenesis: possibilities for therapeutic intervention. Pharm World Sci, 1998; 20(6): 225-235.
2. W Wynendaele, EA de Bruijn, AT van Oosterom. Vascular Endothelial Growth Factor (VEGF) en angiogenese. Aanwinsten in de inwendige geneeskunde, 1998; 25, 189-198.
3. W Wynendaele, MR Christiaens, M Drijkoningen, F Vandekerckhove, R Paridaens, EA de Bruijn, AT van Oosterom. Vroegtijdige detectie van micrometastasen bij patiënten met borstkanker. Nieuwe mogelijkheden? Tijdsch Geneesk, 1999; 55, 507-512.
4. W Wynendaele, R Derua, MF Hoylaerts, A Pawinski, E Waelkens, EA de Bruijn, R Paridaens, W Merlevede, AT van Oosterom. Vascular Endothelial Growth Factor measured in platelet poor plasma allows the best discrimination between cancer patients and volunteers: a key to study an angiogenic marker in vivo? Ann Oncol 1999; 10, 965-973.
5. W Landyut, O Verdoes, DO Darius, M Drijkoningen, S Nuyts, J Theys, L Stockx, W Wynendaele, JF Fowler, G Maleux, W Van den Bogaert, J Anne, AT van Oosterom, P Lambin. Vascular Targeting of solid tumors: a major 'inverse' volume-response relationship following combretastatin A-4 phosphate treatment of rat rhabdomyosarcomas. Eur J Cancer 2000; 36(14): 1833-43.
6. W Wynendaele, EA de Bruijn, AT van Oosterom. Vascular Endothelial Growth Factor (VEGF) en angiogenese. Tijdsch Geneesk, 2000; 56, 64-69.
7. Aerts J, Wynendaele W, Paridaens R, Christiaens MR, Van den Bogaert W, van Oosterom AT, Vandekerckhove P. A real-time quantitative reverse transcriptase polymerase chain reaction (RT-PCR) to detect breast carcinoma cells in peripheral blood. Ann Oncol 2001; 12, 39-46.

8. Groen HJ, de Vries EG, Wynendaele W, Van der Graaf WT, Lechuga MJ, Pogessi I, Dirix LY, van Oosterom AT. PNU-145156E, a novel angiogenesis inhibitor, in patients with solid tumors: a phase 1 and pharmacokinetic study. *Clin Cancer Research* 2001; 7(12): 3928-33.
9. Eskens FA, Dumez H, Hoekstra R, Perschl A, Brindley C, Bottcher S, Wynendaele W, Drevs J, Verweij J, van Oosterom AT. Phase 1 and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins $\alpha v \beta 3$ and $\alpha v \beta 5$ in patients with advanced solid tumors. *Eur J Cancer* 2003; 39(7): 917-926.
10. Ismail MS, Wynendaele W, Aerts JL, Paridaens R, Van Mellaert L, Anne J, Gaafar R, Shakankiry N, Khaled HM, Christiaens MR, Omar S, Vandekerckhove P, Van Oosterom AT. Real-time quantitative RT-PCR and detection of tumour cell dissemination in breast cancer patients: plasmid versus cell line dilutions. *Ann Oncol.* 2003;14(8):1241-5.
11. Ismail MS, Wynendaele W, Aerts JL, Paridaens R, Gaafar R, Shakankiry N, Khaled HM, Christiaens MR, Wildiers H, Omar S, Vandekerckhove P, Van Oosterom AT. Detection of micrometastatic disease and monitoring of perioperative tumor cell dissemination in primary operable breast cancer patients using real-time quantitative reverse transcription-PCR. *Clin Cancer Res.* 2004; 1 (10): 196-201.
12. Castryck H, van den Driessche M, Hagemeyer A, Stul M, Wynendaele W, Vandenberghe P, Moerman J. Coexistence of light chain disease and chronic lymphocytic leukaemia, a complex karyotype with a rapid fatal outcome. *Clin Lab Haematol.* 2006; 28(2):138-40
13. Beuselinck B, Wildiers H, Wynendaele W, Dirix L, Kains JP, Paridaens R. Weekly paclitaxel versus weekly docetaxel in elderly or frail patients with metastatic breast carcinoma: A randomized phase-II study of the Belgian Society of Medical Oncology. *Crit. Rev. Oncol. Hematol.* 2009 Aug 1. Epub ahead of print.

14. Saegeman V, Wynendaele W, Kerre S, Dedeurwaerdere F, Van den Driessche M, Moerman J. Transfusion-induced serum sickness. *Transfusion*. 2009 Feb.; 49(2):372-45. Epub 2008 Oct 28.